论文部分内容阅读
目的比较住院患者使用甘精胰岛素(glargine)和中性鱼精蛋白锌胰岛素(NPH)控制血糖达标的成本。方法92例新诊断的2型糖尿病患者,70例用口服降糖药治疗的2型糖尿病患者以及16例1型糖尿病患者进入本研究,每组等分为两亚组,分别予glargine和NPH,运用药物经济学最小成本分析法比较两种药物的治疗成本。结果3组研究人群均显示,与NPH比较,glargine单药成本(人民币元)高(116．30±18．80 vs 38．68±6．57,190．84±30．37vs53．43±7．15,120．06±10．90 vs 29．51±2．17),每日成本(人民币元)高(431．62±62．18vs 370．16±49．80,356．48±55．46 vs 335．77±41．69,294．12±55．99vs 245．17±29．57),总成本(人民币元)低(2 679．40±92．49 vs 3016．50±174．72,3 629．23±105．55vs 3 821．62±140．25,1 576．55±114．69vs 1 715．85±126．32)。结论使用glargine控制血糖较NPH节约住院成本。
Objective To compare the cost of inpatients with glycemic control using glargine and neutral protamine zinc insulin (NPH). Methods A total of 92 newly diagnosed type 2 diabetic patients, 70 type 2 diabetic patients treated with oral hypoglycemic agents and 16 type 1 diabetic patients were enrolled in this study. Each group was equally divided into two subgroups: glargine and NPH, Use the least cost analysis method of pharmacoeconomics to compare the treatment costs of the two drugs. Results All three study populations showed a higher cost of single glargine (RMB) compared with NPH (116.30 ± 18.80 vs 38.68 ± 6.57, 190.84 ± 30.37 vs. 53.43 ± 7.15, 120). 06 ± 10.90 vs 29.51 ± 2.17), the daily cost (RMB) was higher (431.62 ± 62.18 vs 370.16 ± 49.80,356.48 ± 55.46 vs 335.77 ± 41 .69, 294.12 ± 55.99 vs 245.17 ± 29.57), total cost (RMB) low (2679.40 ± 92.49 vs 3016.50 ± 174.72,3 629.23 ± 105.55 vs 3 821.62 ± 140.25, 1 576.55 ± 114.69 vs 1 715.85 ± 126.32). Conclusion The use of glargine to control blood glucose is more cost effective than NPH in hospitalization.